Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
6 studies found for:    21924492 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Condition: Myelodysplastic Syndromes
Intervention: Drug: Oral rigosertib
2 Completed Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Condition: Myelodysplastic Syndrome
Intervention: Drug: ON 01910.Na
3 Completed Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Conditions: Acute Myelocytic Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelocytic Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndromes
Intervention: Drug: ON 01910.Na
4 Active, not recruiting Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Conditions: Myelodysplastic Syndromes;   Refractory Anemia With Excess Blasts;   Chronic Myelomonocytic Leukemia;   Cytopenia
Intervention: Drug: rigosertib sodium
5 Completed Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Conditions: Myelodysplastic Syndrome;   Acute Myeloid Leukemia
Intervention: Drug: ON 01910.Na
6 Active, not recruiting Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Conditions: Myelodysplastic Syndromes;   MDS;   RAEB;   Chronic Myelomonocytic Leukemia
Intervention: Drug: ON 01910.Na

Study has passed its completion date and status has not been verified in more than two years.